Surmodics, Inc. - Common Stock (NQ:SRDX)

42.98 UNCHANGED

Last Price Updated: 4:00 PM EST, Nov 18, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Surmodics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Dow, Nasdaq Up Triple Digits; CPI Data Still In Focus ↗

June 13, 2023

Stocks are firmly higher this afternoon.

Via Talk Markets

Why Shares of Surmodics Soared on Tuesday ↗

June 13, 2023

An analyst upgrade gave the stock a boost.

Via The Motley Fool

Why Motorcar Parts of America Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

June 13, 2023

Gainers First Wave BioPharma, Inc. (NASDAQ: FWBI) shares gained 143% to $2.77 after the company achieved its enrollment target for its adrulipase Phase 2 SPAN trial for exocrine pancreatic...

Via Benzinga

Surmodics's Return on Invested Capital Insights ↗

April 28, 2023

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

March 15, 2023

On Wednesday, 479 stocks made new 52-week lows.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 13, 2023 ↗

June 13, 2023

Via Benzinga

Top 5 Health Care Stocks That Could Blast Off In May ↗

May 26, 2023

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Via Benzinga

Surmodics to Participate in the Jefferies Healthcare Conference on June 8

May 25, 2023

From Surmodics, Inc.

Via Business Wire

Surmodics Reports Second Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial Guidance

April 26, 2023

From Surmodics, Inc.

Via Business Wire

Surmodics Announces First Patient Enrolled in PROWL Registry Study Using the Pounce™ Thrombectomy System

April 20, 2023

From Surmodics, Inc.

Via Business Wire

Surmodics to Report Second Quarter of Fiscal 2023 Financial Results on April 26

April 19, 2023

From Surmodics, Inc.

Via Business Wire

Surmodics Announces Successful First Patient Use of Sublime™ Radial Access Microcatheter Designed for the Periphery

April 19, 2023

From Surmodics, Inc.

Via Business Wire

Surmodics to Participate in the 22nd Annual Needham Virtual Healthcare Conference on April 20

April 11, 2023

From Surmodics, Inc.

Via Business Wire

Surmodics, Inc. (NASDAQ:SRDX) Shareholder Alert: Investigation Concerning Possible Wrongdoing ↗

April 05, 2023

San Diego, CA -- (SBWIRE) -- 04/05/2023 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Surmodics, Inc.

Via SBWire

Surmodics Provides Regulatory Update on its Strategy to Submit an Amended Premarket Approval Application for the SurVeil™ Drug-Coated Balloon

March 28, 2023

From Surmodics, Inc.

Via Business Wire

Sidoti's Small-Cap Virtual March Conference

March 20, 2023

Via ACCESSWIRE

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation - SRDX

March 18, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation - SRDX

March 12, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation – SRDX

March 09, 2023

From The Rosen Law Firm PA

Via GlobeNewswire

Surmodics to Participate in Upcoming Investor Conferences in March

March 08, 2023

From Surmodics, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Monday ↗

March 06, 2023

On Monday, 36 companies set new 52-week lows.

Via Benzinga

NATIONALLY RANKED ROSEN LAW FIRM Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation - SRDX

March 05, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

SRDX NOTICE: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation – SRDX

March 03, 2023

From The Rosen Law Firm PA

Via GlobeNewswire

Stocks That Hit 52-Week Lows On Tuesday ↗

February 28, 2023

During Tuesday, 79 stocks hit new 52-week lows.

Via Benzinga

ROSEN, A TOP RANKED LAW FIRM, Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation - SRDX

February 26, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation – SRDX

February 23, 2023

From The Rosen Law Firm PA

Via GlobeNewswire

ROSEN, A LEADING LAW FIRM, Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation - SRDX

February 19, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Abbott-Cardiovascular Systems Acquisition Could Further Add Uncertainty Over Surmodics' Product: Analyst Downgrades Stock ↗

February 13, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 13, 2023 ↗

February 13, 2023

Via Benzinga

NATIONALLY RANKED ROSEN LAW FIRM Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation – SRDX

February 09, 2023

From The Rosen Law Firm PA

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.